Search
for
Sort by
Research 30 of 1000+
- Comparison of Different Alpha-blocker Combinations in Male Hypertensives with Refractory Lower Urinary Tract Symptoms
- Prospective randomized study of sexual function in men taking dutasteride for the treatment of androgenetic alopecia
- Testosterone for Low Libido in Postmenopausal Women Not Taking Estrogen: A Phase III Research Study of Female Sexual Dysfunction in Women on Testosterone Patch Without Estrogen (APHRODITE)
- Ovary and uterus related adverse events associated with statin use: an analysis of the FDA Adverse Event Reporting System
- A Randomized Trial of Oral DHEA Treatment for Sexual Function, Well-Being, and Menopausal Symptoms in Postmenopausal Women with Low Libido
- Impact of Alpha Blockers, 5-alpha Reductase Inhibitors and Combination Therapy on Sexual Function
- Safety and Efficacy Assessment of Red Ginseng Oil (RXGIN) in Men with Lower Urinary Tract Symptoms in a Randomized, Double-Blind, Placebo-Controlled Trial
- (024) Monitored Hormone Therapy in Women 70 Years and Older: Aging Does Not Mean Sexual Retirement
- Finasteride in the treatment of men with androgenetic alopecia
- Comments concerning the real risk of sexual adverse events secondary to the use of 5-ARIs
- Safety and efficacy of advanced and targeted acid α-glucosidase (AT-GAA) (ATB200/AT2221) in ERT-switch nonambulatory patients with Pompe disease: preliminary results from the ATB200-02 trial
- MP89-08 POST-FINASTERIDE SYNDROME: REAL OR IMAGINED?
- Differences in reproductive toxicology between alopecia drugs: an analysis on adverse events among female and male cases
- Risk assessment of the top 60 drugs for drug-related sexual dysfunction: a disproportion analysis from the Food and Drug Administration adverse event reporting system
- Multidimensional assessment of adverse events of finasteride：a real-world pharmacovigilance analysis based on FDA Adverse Event Reporting System (FAERS) from 2004 to April 2024
- Oral finasteride use and sexual adverse events: signal detection from disproportionality analyses of data from the United States Food and Drug Administration Adverse Event Reporting System
- Re: Long-Term Consequences of Finasteride vs Placebo in the Prostate Cancer Prevention Trial
- PD49-03 IS TADALAFIL ASSOCIATED WITH DECREASED RISK OF MAJOR ADVERSE CARDIAC EVENTS OR VENOUS THROMBOEMBOLISM IN MEN WITH LOWER URINARY TRACT SYMPTOMS?
- A Gender Hypothesis of sex disparities in adverse drug events
- Persistent Sexual Dysfunction and Suicidal Ideation in Young Men Treated with Low-Dose Finasteride: A Pharmacovigilance Study
- Negative Impact of Testosterone Deficiency and 5α-Reductase Inhibitors Therapy on Metabolic and Sexual Function in Men
- Endocrine care of transpeople part I. A review of cross-sex hormonal treatments, outcomes and adverse effects in transmen
- Safety Analysis of Panax Ginseng in Randomized Clinical Trials: A Systematic Review
- Repurposing steroidogenesis inhibitors for the therapy of neuropsychiatric disorders: Promises and caveats
- The Dark Side of 5α-Reductase Inhibitors' Therapy: Sexual Dysfunction, High Gleason Grade Prostate Cancer and Depression
- How routine pharmacovigilance failed to identify finasteride’s persistent sexual side effects
- The Impact of the 5α-Reductase Inhibitors (5α-RIs) on Male Sexual Function and Psychological Well-Being
- Effects of 5-alpha reductase inhibitors on erectile function, sexual desire and ejaculation
- Signal Detection of Depression and Suicidality Associated with Finasteride and Dutasteride: Updated Pharmacovigilance Evidence and Recommendations for Comprehensive Psychiatric Assessment
- Is the Safety of Finasteride Correlated With Its Route of Administration: Topical Versus Oral? A Pharmacovigilance Study With Data From the United States Food and Drug Administration Adverse Event Reporting System